Emerging drugs for the treatment of alopecia areata.
Expert Opin Emerg Drugs
; 27(4): 379-387, 2022 12.
Article
em En
| MEDLINE
| ID: mdl-36408593
INTRODUCTION: Alopecia Areata (AA) is the second most common non-scarring hair loss disorder, with a prevalence of 1 in 1000 and a lifetime incidence of 2% worldwide. Data from a recent American study shows that from 68,121 patients with the diagnosis of AA, 37,995 (55.8%) were prescribed treatment for AA within a year of diagnosis, however there are still no therapies able to induce permanent remission, or treatments that guarantee hair regrowth/remissions in 100% of cases, especially in longstanding/severe AA. Recently, oral baricitinib has been approved for AA, being the first drug approved for this specific indication. AREAS COVERED: The current review will provide a summary of current pharmacological approaches and novel therapeutics in development. EXPERT OPINION: New and very effective drugs have become available for the treatment of severe AA, and many others are expected soon. However, even new, effective treatments are not effective in all patients and recurrence rates after treatment interruption are high. AA is a systemic disease with important impact on quality of life and should not be considered just as an aesthetic problem. Treatment of the disease should take in account and possibly also address treatment of comorbidities.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Alopecia em Áreas
/
Inibidores de Janus Quinases
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article